GLP1R and neoplasm: This conclusion was supported by a meta-analysis including 50,453 patients from randomized controlled trials, assessing the incidence of neoplasms in type 2 diabetic patients receiving GLP-1 receptor agonists compared with placebo or other hypoglycemic drugs; in this study, there was no increase in malignant neoplasm formation upon GLP-1 agonist use [83].